Arrowhead Pharmaceuticals Inc.
(NASDAQ:ARWR) stock is trading higher on Wednesday as the company revealed successful topline outcomes from its late-stage SHASTA-3 and SHASTA-4 trials evaluating plozasiran in individuals suffering from severe hypertriglyceridemia.
Hypertriglyceridemia is the presence of high levels of triglycerides (a type of fat) in the blood.
The disease substantially raises the likelihood of fatal acute pancreatitis and frequent hospitalizations.
Read Also: Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market Trial Outcomes And Efficacy Highlights Both Phase 3 investigations successfully achieved their primary milestone by cutting triglyceride levels compared to a placebo.
